Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

University of California, Irvine

Summary

This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * ≥18 years of age * Have a diagnosis of myelofibrosis (MF) according to the 2016 WHO criteria * Has a hemoglobin ≤ 10gm/dL at screening * Serum ferritin ≥ 100 * May continue on current MPN treatment, including aspirin, hydroxyurea, interferon-alpha, ruxolitinib, fedratinib, or anagrelide. * Peripheral blast count \<10% during Screening. * Free of other known active or metastatic malignancies other than localized skin cancer. * Amenable to blood draws and symptom assessments. * Agree to the use of contraceptives. Female subjects of childbearing potential and their male par…

Interventions

Drug
Nelfinavir
Taken twice daily

Location

Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California
ucstudy@uci.edu 877-827-8839

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions